Department of Radiology, School of Medicine, Ewha Womans University, Seoul, South Korea.
Division of Breast Surgery, Department of Surgery, School of Medicine, Ewha Womans University, Seoul, South Korea.
Breast Cancer Res Treat. 2024 Jul;206(1):31-44. doi: 10.1007/s10549-024-07272-3. Epub 2024 May 14.
This single-center, randomized, prospective, exploratory clinical trial was conducted to assess the clinical efficacy of an augmented reality (AR)-based breast cancer localization imaging solution for patients with breast cancer.
This clinical trial enrolled 20 women who were diagnosed with invasive breast cancer between the ages of 19 and 80, had a single lesion with a diameter ≥ 5 mm but ≤ 30 mm, had no metastases to other organs, and had not received prior chemotherapy. All patients underwent mammography, ultrasound, computed tomography, and magnetic resonance imaging for preoperative assessment. Patients were randomly assigned to ultrasound-guided skin marking localization (USL) and AR-based localization (ARL) groups (n = 10 in each group). Statistical comparisons between USL and ARL groups were made based on demographics, radiologic features, pathological outcomes, and surgical outcomes using chi-square and Student t-tests.
Two surgeons performed breast-conserving surgery on 20 patients. Histopathologic evaluation of all patients confirmed negative margins. Two independent pathologists evaluated the marginal distances, and there were no intergroup differences in the readers' estimates (R1, 6.20 ± 4.37 vs. 5.04 ± 3.47, P = 0.519; R2, 5.10 ± 4.31 vs. 4.10 ± 2.38, P = 0.970) or the readers' average values (5.65 ± 4.19 vs. 4.57 ± 2.84, P = 0.509). In comparing the tumor plane area ratio, there was no statistically significant difference between the two groups in terms of either reader's mean values (R1, 15.90 ± 9.52 vs. 19.38 ± 14.05, P = 0.525; R2, 15.32 ± 9.48 vs. 20.83 ± 12.85, P = 0.290) or the overall mean values of two readers combined (15.56 ± 9.11 vs. 20.09 ± 13.38, P = 0.388). Convenience, safety, satisfaction, and reusability were all superior in the AR localization group (P < 0.001) based on the two surgeons' responses.
AR localization is an acceptable alternative to ultrasound-guided skin marking with no significant differences in surgical outcomes.
本单中心、随机、前瞻性、探索性临床试验旨在评估一种基于增强现实(AR)的乳腺癌定位成像解决方案在乳腺癌患者中的临床疗效。
本临床试验纳入了 20 名年龄在 19 至 80 岁之间、诊断为浸润性乳腺癌、病灶直径≥5mm 但≤30mm、无其他器官转移、且未接受过化疗的女性患者。所有患者均接受了术前评估的乳腺 X 线摄影、超声、计算机断层扫描和磁共振成像检查。患者被随机分配至超声引导皮肤标记定位(USL)和基于 AR 的定位(ARL)组(每组 10 名患者)。使用卡方检验和学生 t 检验比较 USL 和 ARL 组之间的统计学差异,比较的内容包括人口统计学特征、影像学特征、病理结果和手术结果。
两位外科医生对 20 名患者进行了保乳手术。所有患者的组织病理学评估均证实切缘阴性。两位独立的病理学家评估了边缘距离,读者估计值(R1,6.20±4.37 与 5.04±3.47,P=0.519;R2,5.10±4.31 与 4.10±2.38,P=0.970)或读者平均值(R1,5.65±4.19 与 4.57±2.84,P=0.509)在两组间无统计学差异。在比较肿瘤平面面积比时,两组在读者平均值(R1,15.90±9.52 与 19.38±14.05,P=0.525;R2,15.32±9.48 与 20.83±12.85,P=0.290)或两位读者的总体平均值(R1,15.56±9.11 与 20.09±13.38,P=0.388)方面均无统计学差异。基于两位外科医生的回答,在便利性、安全性、满意度和可重复使用性方面,AR 定位组均优于超声引导皮肤标记定位组(P<0.001)。
AR 定位是超声引导皮肤标记的一种可接受的替代方法,在手术结果方面无显著差异。